Skip to main content

Table 2 Median values (ranges) of measures of irradiation of both lungs excluding iGTV, at baseline and after re-optimization, and two-sided significances of changes in distributions of these measures following re-optimization

From: Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer

Dose-volume measure

At baseline

After MDHeart reduction

After VHeart-50-Gy reduction

After VLAwall-63-Gy reduction

EQD2Lung-mean*

13.7 Gy (8.0, 16.8 Gy)

13.9 Gy (7.2, 16.6 Gy)

p = 0.03

13.7 Gy (7.7, 16.7 Gy)

p = 0.07

14.1 Gy (8.0, 16.8 Gy)

p = 0.86

Mean lung dose

15.7 Gy (9.4, 19.5 Gy)

15.8 Gy (8.5, 19.3 Gy)

p = 0.03

15.7 Gy (9.1, 19.4 Gy)

p = 0.06

16.0 Gy (9.4, 19.5 Gy)

p = 0.89

VLung-10-Gy**

47.2% (29.0,70.9%)

46.3% (27.6, 73.9%)

p = 5 × 10–3

46.5% (29.0, 76.5%)

p = 0.16

47.5% (29.0, 77.4%)

p = 0.88

VLung-20-Gy

27.2% (15.6, 34.4%)

28.1% (13.6, 34.8%)

p = 0.98

26.4% (14.9, 34.5%)

p = 0.30

26.4% (15.6, 34.9%)

p = 0.94

VLung-30-Gy

17.1% (7.9, 23.7%)

16.4% (6.7, 24.5%)

p = 0.59

16.7% (7.7, 23.7%)

p = 8 × 10–3

16.6% (7.9, 23.7%)

p = 0.72

VLung-50-Gy

7.0% (2.6, 12.2%)

6.9% (2.2, 14.4%)

p = 1.00

7.0% (2.4, 12.6%)

p = 0.05

7.5% (2.6, 12.2%)

p = 0.30

  1. *Equivalent dose in 2 Gy fractions averaged across both lungs minus iGTV
  2. **The fraction of both lungs minus iGTV receiving ≥ 10 Gy